<DOC>
	<DOC>NCT01681212</DOC>
	<brief_summary>The purpose of this study is to determine the survival rate after 1 year of treatment with ipilimumab plus dacarbazine in patients with previously untreated Stage III (unresectable) or Stage IV melanoma.</brief_summary>
	<brief_title>Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key inclusion criteria: Japanese patients with histologic diagnosis of malignant melanoma Previously untreated Stage III with N3 (unresectable) or Stage IV melanoma Prior adjuvant melanoma therapy permitted Eastern Cooperative Oncology Group performance status of 0 or 1 Life expectancy of at least 16 weeks in this study Adequate bone marrow and renal and hepatic function, specifically: white blood cell count ≥2500/uL, absolute neutrophil count ≥1000/uL, platelet count ≥75,000/uL, hemoglobin level ≥9.0 g/dL, creatinine level ≤2.5*upper limit of normal (ULN), aspartate transaminase/alanine transaminase level &lt;2.5*ULN for patients without liver metastasis and &lt;5*ULN for patients with liver metastasis, total bilirubin level &lt;1.5*ULN (for those with Gilbert's Syndrome, lower than 3.0 mg/dL) Key exclusion criteria: Evidence of brain metastases on brain imaging Active brain metastases with symptoms or requiring corticosteroid treatment; patients with any other malignancy from which they have been diseasefree for fewer than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix Primary ocular or mucosal melanoma History of or current active autoimmune disease History or concurrent disease of gastrointestinal perforations HIV infection; active Hepatitis B or C or human Tlymphotropic virus type1 infection, based on testing performed during the screening period of this study Prior or concomitant therapy with any anticancer agent for melanoma, or other investigational anticancer therapies Prior adjuvant therapy &lt;4 weeks prior to the start of study drug administration Concomitant therapy with immunosuppressive agents, surgery, or radiotherapy Prior treatment with CTLA4 inhibitors/agonists or other experimental immunotherapy drugs Treatment with other investigational products within 4 weeks prior to initial treatment of study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>